000910744 001__ 910744
000910744 005__ 20221219115115.0
000910744 0247_ $$2doi$$a10.1007/s00259-019-04426-0
000910744 0247_ $$2ISSN$$a0340-6997
000910744 0247_ $$2ISSN$$a1432-105X
000910744 0247_ $$2ISSN$$a1619-7070
000910744 0247_ $$2ISSN$$a1619-7089
000910744 0247_ $$2Handle$$a2128/32630
000910744 0247_ $$2pmid$$a31342134
000910744 0247_ $$2WOS$$aWOS:000502971900023
000910744 037__ $$aFZJ-2022-04114
000910744 082__ $$a610
000910744 1001_ $$0P:(DE-HGF)0$$aSehlin, Dag$$b0
000910744 245__ $$aEngineered antibodies: new possibilities for brain PET?
000910744 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2019
000910744 3367_ $$2DRIVER$$aarticle
000910744 3367_ $$2DataCite$$aOutput Types/Journal article
000910744 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1668667675_29672
000910744 3367_ $$2BibTeX$$aARTICLE
000910744 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000910744 3367_ $$00$$2EndNote$$aJournal Article
000910744 520__ $$aAlmost 50 million people worldwide are affected by Alzheimer's disease (AD), the most common neurodegenerative disorder. Development of disease-modifying therapies would benefit from reliable, non-invasive positron emission tomography (PET) biomarkers for early diagnosis, monitoring of disease progression, and assessment of therapeutic effects. Traditionally, PET ligands have been based on small molecules that, with the right properties, can penetrate the blood-brain barrier (BBB) and visualize targets in the brain. Recently a new class of PET ligands based on antibodies have emerged, mainly in applications related to cancer. While antibodies have advantages such as high specificity and affinity, their passage across the BBB is limited. Thus, to be used as brain PET ligands, antibodies need to be modified for active transport into the brain. Here, we review the development of radioligands based on antibodies for visualization of intrabrain targets. We focus on antibodies modified into a bispecific format, with the capacity to undergo transferrin receptor 1 (TfR1)-mediated transcytosis to enter the brain and access pathological proteins, e.g. amyloid-beta. A number of such antibody ligands have been developed, displaying differences in brain uptake, pharmacokinetics, and ability to bind and visualize the target in the brain of transgenic mice. Potential pathological changes related to neurodegeneration, e.g. misfolded proteins and neuroinflammation, are suggested as future targets for this novel type of radioligand. Challenges are also discussed, such as the temporal match of radionuclide half-life with the ligand's pharmacokinetic profile and translation to human use. In conclusion, brain PET imaging using bispecific antibodies, modified for receptor-mediated transcytosis across the BBB, is a promising method for specifically visualizing molecules in the brain that are difficult to target with traditional small molecule ligands.Keywords: Alzheimer’s disease (AD); Amyloid-β (Aβ); Antibody; Blood–brain barrier (BBB); Positron emission tomography (PET); Transferrin receptor 1 (TfR1)-mediated transcytosis.
000910744 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000910744 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000910744 7001_ $$0P:(DE-HGF)0$$aSyvänen, Stina$$b1$$eCorresponding author
000910744 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b2
000910744 7001_ $$0P:(DE-HGF)0$$afaculty, MINC$$b3
000910744 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-019-04426-0$$gVol. 46, no. 13, p. 2848 - 2858$$n13$$p2848 - 2858$$tEuropean journal of nuclear medicine and molecular imaging$$v46$$x0340-6997$$y2019
000910744 8564_ $$uhttps://juser.fz-juelich.de/record/910744/files/Engineered%20antibodies.pdf$$yOpenAccess
000910744 909CO $$ooai:juser.fz-juelich.de:910744$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000910744 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Rudbeck Laboratory, 75185, Uppsala, Sweden.$$b0
000910744 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a  Department of Public Health and Caring Sciences/Geriatrics, Uppsala University, Rudbeck Laboratory, 75185, Uppsala, Sweden. stina.syvanen@pubcare.uu.se.$$b1
000910744 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b2$$kFZJ
000910744 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000910744 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2019$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-02-02$$wger
000910744 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000910744 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2019$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-02-02
000910744 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-02
000910744 920__ $$lyes
000910744 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000910744 980__ $$ajournal
000910744 980__ $$aVDB
000910744 980__ $$aUNRESTRICTED
000910744 980__ $$aI:(DE-Juel1)INM-2-20090406
000910744 9801_ $$aFullTexts